DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/blvjbn/community) has announced the addition of the "Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Furiex Pharmaceuticals, Inc.
- Galapagos NV
- Novan, Inc.
Drug Profiles
- acorafloxacin
- GLPG-1492
- NVN-1000
- NVN-4428
- Synthetic Peptide for Multi-Drug Resistant Bacterial Infections
For more information visit http://www.researchandmarkets.com/research/blvjbn/community